These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25361983)

  • 1. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.
    Kobayashi Y; Mitsudomi T; Sakao Y; Yatabe Y
    Ann Oncol; 2015 Jan; 26(1):156-161. PubMed ID: 25361983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
    Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
    J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT-Assisted Improvements in the Accuracy of the Intraoperative Frozen Section Examination of Ground-Glass Density Nodules.
    Xinli W; Xiaoshuang S; Chengxin Y; Qiang Z
    Comput Math Methods Med; 2022; 2022():8967643. PubMed ID: 35035526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
    Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
    Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung Adenocarcinoma Invasiveness Risk in Pure Ground-Glass Opacity Lung Nodules Smaller than 2 cm.
    Lee GD; Park CH; Park HS; Byun MK; Lee IJ; Kim TH; Lee S
    Thorac Cardiovasc Surg; 2019 Jun; 67(4):321-328. PubMed ID: 29359309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation exploration among CT imaging, pathology and genotype of pulmonary ground-glass opacity.
    Cai Y; Chen T; Zhang S; Tan M; Wang J
    J Cell Mol Med; 2023 Jul; 27(14):2021-2031. PubMed ID: 37340599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in quantitative CT image features of ground-glass nodules in differentiating invasive pulmonary adenocarcinoma from benign and in situ lesions: histopathological comparisons.
    Zhang YP; Heuvelmans MA; Zhang H; Oudkerk M; Zhang GX; Xie XQ
    Clin Radiol; 2018 May; 73(5):504.e9-504.e16. PubMed ID: 29329732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
    Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
    Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.
    Ko SJ; Lee YJ; Park JS; Cho YJ; Yoon HI; Chung JH; Kim TJ; Lee KW; Kim K; Jheon S; Kim H; Lee JH; Lee CT
    BMC Cancer; 2014 May; 14():312. PubMed ID: 24885886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
    Serizawa M; Koh Y; Kenmotsu H; Isaka M; Murakami H; Akamatsu H; Mori K; Abe M; Hayashi I; Taira T; Maniwa T; Takahashi T; Endo M; Nakajima T; Ohde Y; Yamamoto N
    Cancer; 2014 May; 120(10):1471-81. PubMed ID: 24700479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
    Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
    Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
    Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
    Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HRCT features distinguishing pre-invasive from invasive pulmonary adenocarcinomas appearing as ground-glass nodules.
    Zhang Y; Shen Y; Qiang JW; Ye JD; Zhang J; Zhao RY
    Eur Radiol; 2016 Sep; 26(9):2921-8. PubMed ID: 26662263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.